Medtronic received information via literature regarding long-term clinical results after freestyle stentless aortic root bioprosthesis replacement.All data were collected from a single center between january 2003 and december 2008.The study population included 77 patients (predominantly male, mean age 68.7 years), all of which were implanted with a medtronic freestyle stentless aortic bioprosthetic valve (unique device identifier numbers not provided).Among all patients, there were 2 in-hospital deaths and 14 late deaths during the follow-up period (median of 11.2 years).Four of the late deaths were deemed valve-related and were attributed to endocarditis (n=2), thromboembolism (n=1) , and congestive heart failure (n=1).No further details were provided on these four deaths.Based on the available information medtronic product was directly associated with the four deaths.Among all patients, adverse events included: transient ischemic attack (n=4), moderate pleural effusion (n=2), superficial wound infection(n=2), bleeding (n=3) requiring surgical intervention, structural valve deterioration (n=3) with stenosis or regurgitation requiring a valve-in-valve procedure, and endocarditis (n=1) requiring reoperation to replace the aortic root.Based on the available information medtronic product may have been associated with the adverse event(s).No additional adverse patient effects or product performance issues were reported.
|